Oxysure Systems Inc (OTCMKTS:OXYS) recently made a big move up off its $0.43 low’s to highs of $1.40. Since then the stock has come down some but is consolidating well.
OXYS got caught up in the Ebola penny stocks frenzy after the Company announced in the beginning of November that they were launching an Ebola Intervention Kit designed to provide caregivers two critical tools for the early treatment of Ebola patients or for anyone showing possible Ebola symptoms.
Oxysure Systems Inc (OTCMKTS:OXYS) was formed in 2004 to develop products capable of producing medical grade oxygen “on demand,” without the necessity of storing oxygen in compressed tanks.
Early on OXYS pioneered the OxySure Model 615; a safe and easy to use solution to produce medically pure (USP) oxygen by combining two inert powders. As there is no pressurization or oxygen until the powders are combined, there’s no threat of flammability or explosion as there is with pressurized oxygen.
The device was approved by the FDA in 2005 and the Company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems.
Back in October OXYS merged with Estill Medical Technologies creating a combined firm that is expected to generate $10 million in annual sales according the release.
To Find out the inside Scoop on OXYS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
OXYN CEO, Julian Ross commented, “Bringing our two companies together is a great development not only for us, but for our customers, who will benefit from our unique and innovative products, available through a broader, multi-channel, global distribution network. The combined entity creates a shared and leveraged business platform that optimizes Business Operations, Manufacturing & Distribution, Research & Development and Sales & Marketing. This transaction represents the first step towards enhancing our platform of proven, life-saving products geared towards enabling first-responders.”
Then on November 4 OXYS announced the launch of an Ebola Intervention Kit which was designed to provide caregivers two critical tools for the early treatment of Ebola patients or for anyone showing possible Ebola symptoms.
The “Ebola Intervention Kit” (Product reference number TA-OXYS-EIK) consists of the Thermal Angel Blood and IV Fluid Warmer and the OxySure 615 Portable Emergency Oxygen System. The companies are also in discussions with other suppliers to possibly expand the kit in a modular way.
OXYS recently reported operating results for the third quarter 2014. Highlights include 3 month revenues of $818,456, up 50%, 9 month revenues of $1,852,796, up 47% and Trailing 12 months sales $2.4 million.
Conclusion: OXYS is making an explosive move up after some needed consolidation. The stock has benefited from the massive publicity surrounding the Ebola crisis in West Africa as the Company recently launched an Ebola Intervention Kit designed to provide caregivers two critical tools for the early treatment of Ebola patients or for anyone showing possible Ebola symptoms.
We have a Monster Pick Coming. Subscribe Right Now!
The demand for OXYS products continues to grow quickly as the public becomes aware of the need for medically pure (USP) oxygen that is easily accessible in public places. Already OXYS has built a number of valuable distribution agreements responsible for the Company’s fast growing revenues.
OXYS has exploded out of obscurity in recent weeks and is quickly becoming one of the top traded stocks on the bb’s. The stock looks to be under heavy accumulation as investors bet the Ebola connection will continue to drive prices higher.
WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?
Disclosure: we hold no position in OXYS either long or short and we have not been compensated for this article.